The incidence and prevalence of chronic kidney disease (CKD) 
, S M TAJDIT RAHMAN 3 , KHALEDA AKHTER 4 , ADIBA TARANNUM 5 , KHWAJA NAZIM UDDIN highest risk category for coronary heart disease CHD 2 . The incidence of cardiovascular disease CVD is high in patient on haemodialysis 3 .
CKD is defined as abnormalities of kidney structure or function, present for 3 months, with implications for health. It is diagnosed most frequently by the presence of micro albuminuria. Levels of urinary albumin excretion above 30 mg/day on at least 2 measurements are consistent with CKD, regardless of the level of the GFR. 4, 5, 6 We will focus primarily on the dyslipidaemia in patients with stage -3, stage-4, stage-5 CKD on conservative treatment and maintenance haemodialysis. Dyslipidaemia in common in patients with CKD and lipid profile varies widely depending on the level of kidney function and the degree of proteinurea. 7 In CKD, the etiology of dyslipidemia may be reflected more accurately in the apolipoprotein profile. Levels of apoA-I and apoA-II are often reduced yielding decreased production of HDL-C. In addition, apoC-III, integral for the metabolism of both LDL-C and very low-density lipoprotein cholesterol (VLDL-C) is present in elevated levels. The accumulation of apoBcontaining VLDL particles is also important in the development and maintenance of dyslipidemia in CKD. 8, 9 Factors that may contribute to decreased catabolism and clearance of triglyceride -rich apoBcontaining lipoproteins include 1) reduced activity of lipolytic enzymes; 2) compositional abnormalities in lipoproteins preventing binding to appropriate receptors, and 3) decreased uptake of lipoproteins from the circulation. 10 Binding and uptake of lipoproteins may be affected by increased amounts of oxidant stress seen in CKD such that oxidative modification of lipoproteins leads to decreased uptake by the appropriate receptors and subsequent atherosclerosis. 11 In summary multiple factors interfere with uptake of triglyceride-rich apoBcontaining lipoproteins by the liver and in the periphery, yielding increased circulation of these potentially atherogenic lipoproteins. 12 Prior to developing CKD, patient frequently have elevated total and LDL-C levels. However as CKD advances to kidney failure, the prevalence of elevated total and LDL-C levels decreases. In dialysis patient LDL-C levels generally are lower than in general population. 13, 14, 15. The classic lipid profile of later stage CKD includes hyper triglyceridemia, low HDL-C, and low or normal LDL-C. 16 Keeping in view the mortality in CKD patients, we investigate the serum lipid status in CKD patient undergoing on conservative treatment and maintenance haemodialysis. Identification of CKD as a major risk factor for cardiovascular morbidity and mortality is attributed to dyslipidemia, and therefore an expectation of effective intervention to diminish premature cardiovascular mortality and progression of renal disease to increase longevity is imperative, thus this study explore the lipid profile in chronic renal failure patient; on conservative treatment and maintenance haemodailysis treatment. Continuous data was presented as mean and standard deviation from the mean and was compared using student's ttest. Categorical data was expressed as percentage and evaluated using chi-square test. P value < 0.05 was considered significant.
Materials and Methods

Results
The Socio-demographic characteristics of the respondents are shown in Table- On average cholesterol, LDL and triglyceride level were more in group B than group A. But statistically these differences were not significant. On the other hand, HDL level was more in group A than group B and it was also statistically insignificant difference. At the same time average LDL/HDL ratio was higher in group B (3.86±1.93) than group A (3.43±1.85). But it was not statistically significant. 
Discussion
Chronic kidney disease (CKD) is a public health problem worldwide because of the increasing prevalence of type 2 diabetes mellitus and atherosclerosis-related renal disease. This creates an important health care problem because a high proportion of these patients will need renal replacement therapy. 17 Outcomes of chronic kidney disease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease.
The worldwide rise in the number of patient with CKD and consequent end-stage renal failure necessitating renal replacement therapy is threatening to reach great proportions over the next decade, and only a small number of countries have robust economies able to meet the challenges posed. A change in global approach to CKD from treatment of ESRD to much more aggressive primary and secondary prevention is therefore imperative. A global and concerted approach to CKD must be adopted in both more and less developed countries to avoid a major catastrophe.
Dyslipidemia is often observed in patients with CKD, resulting in abnormal concentrations and composition of plasma lipoproteins. The prominent features of uremic dyslipidemia are an increase in plasma triglycerides and cholesterol in nearly all lipoproteins, and a reduction in HDL cholesterol.
The underlying mechanisms behind hypertriglyceridemia may indeed be multifactorial. Hypertriglyceridemia are indeed contribute to the progression of atherosclerosis and cardiovascular disease. Cardiovascular disease (CVD) is a major cause of mortality in patients with CKD, caused by numerous factors defined as traditional and uremiarelated risk factors. One of these risk factors, dyslipidemia is often observed in patients with CKD, resulting in abnormal concentrations and composition of plasma lipoproteins. The prominent features of uremic dyslipidemia are an increase in plasma triglycerides, slight increase in LDL and total cholesterol with increase in nearly all lipoproteins, and a reduction in HDL cholesterol. Therefore, it is essential to study the putative mechanisms for uremic dyslipidemia, since optimal treatment is essential for the prevention or delay of cardiovascular complications in patients with CKD.
Although lipid metabolism disorders have been consistently shown to predict atherosclerosis progression and subsequent CVD in the general population, their clinical implications in CKD patients are less clear.
the clinical implications of dyslipidemia in CKD patients are not limited solely to the development of atherosclerotic CVD but may also include an impact on the progression of renal insufficiency. Results, however, have been inconsistent as studies have shown detrimental effects of high concentrations of triglycerides, triglyceride-rich lipoproteins, apoB and total cholesterol, low levels of HDL-cholesterol or no associations at all. 18 On average cholesterol, LDL and triglyceride level were more in group B than group A. On the other hand, HDL level was more in group A than group B and it was also statistically insignificant difference. At the same time average LDL/HDL ratio was higher in group B than group A. But all these differences were statistically insignificant.
Among the group A patients average triglyceride, total cholesterol and LDL level were higher in stage 4 CKD patients than stage 5 CKD patients. Average HDL level was higher in stage 5 CKD patients than stage 4 CKD patients. Among the group B patients average triglyceride and LDL level were higher in stage 4 CKD patients. But none of these two differences were statistically significant. On the other hand, average total cholesterol level was higher in stage 3 CKD patients and it was statistically significant (p<0.05).
On average HDL level was higher in stage 5 patients. But this difference was not statistically significant. In group A LDL/HDL ratio was more in stage 4 CKD patients and it was statistically significant(p<0.05). Average LDL/HDL ratio was highest in stage 4 CKD patients in group B and it was statistically significant (p<0.05). Similarly, a study done in Argentina, 20 on lipid abnormalities in chronic renal failure patients undergoing haemodialysis. Lipid abnormalities were common in patients with renal disease, probably contributing to the high incidence of cardiovascular diseases in this population. In the study they determined the plasma and erythrocyte lipid profile in patients with chronic renal failure (CRF) along 30 months under haemodialysis. They conclude that CRF patients under regular haemodialysis evidence a gradual deterioration in the fatty acid and triglyceride abnormalities, a finding that might be relevant to the risk of cardiovascular disease in this setting.
Although optimum care had been tried in every step of this study, still some limitations existed. Single hospital based study, small sample size, sampling technique, exclusion of CKD stage 1 & 2, cofounders are the major limitations of the study. Though there is no statistical significance between two groups, but overall lipid profile is good in the patients who are on haemodyalysis. Small sample size may not reflect the whole scenario by statistical significance. A multicentric prospective study involving larger number of study population giving adequate statistical power is recommended for conclusive comment on the possible factors associated with dyslipidaemia in CKD patients.
Conclusion
Dyslipidemia represents an integral component of CKD, but it level depends on treatment moralities.
Our study had showed that mean lipid profile is better in patients of CKD on dialysis than those on conservative treatment, but there is no statistical signifcance as sample size very small. When planning therapeutic approaches for CKD patients lipid profile should always be taken into consideration and identification and treatment of it should be an integral part of CKD patients management protocol.
